Mucosal healing plays a critical role in combatting the effects of inflammatory bowel disease,
fistulae and ulcers. While most treatments for such diseases focus on systemically delivered …

Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat
certain gastrointestinal disorders. It is fast emerging as an important target for the …

Drug platforms that enable the directed delivery of therapeutics to sites of diseases to
maximize efficacy and limit off-target effects are needed. Here, we report the development of …

Living bacteria therapies have been proposed as an alternative approach to treating a broad
array of cancers. In this study, we developed a genetically encoded microbial encapsulation …

Background & Aims: Effective therapeutics for treating acute colitis, caused by disruption of
the intestinal epithelial barrier, are scarce. Trefoil factors (TFF) are cytoprotective and …

For therapies targeting diseases of the gastrointestinal tract, we and others envision
probiotic bacteria that synthesize and excrete biotherapeutics at disease sites. Toward this …

Engineered microbes are rapidly being developed for the delivery of therapeutic modalities
to sites of disease. Escherichia coli Nissle 1917 (EcN), a genetically tractable probiotic with …

Here, we report a pathomimetic Leaky Gut Chip that recapitulates increased epithelial
permeability and intestinal inflammation to assess probiotic intervention as live …

Probiotics are living microorganisms that are increasingly used as gastrointestinal
therapeutics by virtue of their innate or engineered genetic function. Unlike abiotic …

Genetically engineered microbes, especially Escherichia coli, have been widely used in the
biosynthesis of proteins and metabolites for medical and industrial applications. As a …